Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml

• Status: Unknown status
• Trial end date: 2017-12-01

Summary

This cross-over study will investigate the efficacy and safety of BIMMD and TUDPF in a clinical setting.

• Phase: Phase 4

Details

• Lead Sponsor: Universitaire Ziekenhuizen Leuven
• Collaborator: Allergan
• Treatments: Bimatoprost; Ophthalmic Solutions; Pharmaceutical Solutions; Tetrahydrozoline